Related Experiment Video
Updated: Jul 4, 2026
04:56
Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
Published on: August 4, 2023
Hypercoagulability and lung cancer.
Felipe Costa de Andrade Marinho1, Teresa Yae Takagaki
1Department of Pulmonology of University of São Paulo School of Medicine, São Paulo, Brasil. fca.marinho@gmail.com
Summary
Cancer patients face increased risks of blood clots due to coagulation system activation by cancer cells or treatments. Understanding these mechanisms is key for developing new cancer therapies and improving patient outcomes.
Area of Science:
- Oncology
- Hematology
- Thrombosis
Background:
- The link between cancer and coagulopathy (blood clotting disorders) has been recognized for over a century.
- Cancer patients exhibit a higher incidence of thromboembolic events, often linked to neoplastic cells or cancer therapies.
- These clotting events can be the initial sign of cancer and may recur even with anticoagulation therapy.
Purpose of the Study:
- To explore the intricate relationship between cancer and the coagulation system.
- To understand how coagulation system activation contributes to cancer progression and metastasis.
- To highlight promising future therapeutic strategies targeting cancer-associated coagulopathy.
Main Methods:
- Review of existing literature on cancer-associated coagulopathy.
- Analysis of mechanisms linking neoplastic cells and therapies to coagulation activation.
- Examination of the impact of coagulation on primary tumors versus metastatic foci.
Main Results:
- Coagulation system activation, triggered by cancer, contributes to disease progression, particularly affecting metastatic sites.
- Thromboembolic events are a significant concern in oncology patients.
- The effectiveness of low-molecular-weight heparins in small cell lung cancer suggests therapeutic potential.
Conclusions:
- The coagulation system, normally involved in healing, becomes dysregulated in cancer, promoting metastasis.
- Further research into cancer-coagulation interactions is crucial for developing novel treatments.
- Targeting coagulation pathways offers promising avenues for managing cancer progression and improving survival rates.
Related Concept Videos
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...